Humira (adalimumab)

WITHDRAWN · PHASE2 · Asthma

Unknown stopping reason

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.